pharmaceuticals – CRI Report

Pharmacy Retail Market in India 2019

admin — Sat, 12 Sep 2020 05:19:50 +0000

Pharmacy Retail Market in India

The pharmacy retail market in India has witnessed significant growth over the past few years, owing to favourable demographic factors and an epidemiological transition. In terms of revenue, the pharmacy retail market in India was valued at INR 996.68 Bn in 2016 and is projected to reach INR 2,330.20 Bn by 2024, expanding at a CAGR of 10.08% during the 2019-2024 period.

The market is majorly occupied by unorganized local players. However, the unorganized sector is anticipated to face intense competition from organized players and online retailers.

Market segmentation based on retail channel:
Based on the retail channel, the market is segmented into organized sector, unorganized sector, and online retail. The unorganized sector accounted for the largest market share (~93.00%) in 2018.

The market share of the organized sector, which consists of licensed and registered players, is estimated to increase steadily over the forecast period.

The online retail segment is projected to expand at a CAGR of ~33.95% during the 2019-2024 period, owing to strong digital infrastructure in the country.

Market segmentation based on drug type:
The generic drugs segment dominated the retail pharmacy market in India, followed by the OTC drugs and patented drugs segments. The low price of generic drugs attributed to its leading share.

The OTC drugs segment is predicted to be the second-leading segment of the pharmacy retail market with a share of ~22.40% in 2024. The inclusion of various medicines under the OTC category, coupled with a preference towards self-medication is predicted to drive the growth of the OTC drugs segment.

The market share of the patented drugs segment is estimated to increase by 5.4% from 2018 to 2024, owing to the launch of various patented drugs in the Indian market.

Market segmentation based on therapeutic area:
In terms of revenue, anti-infectives was the largest therapeutic segment of the India pharmacy retail market in 2018, followed by the cardiac, gastrointestinal, and anti-diabetic segments. The cardiac therapeutic segment is estimated to surpass the anti-infectives segment during the forecast period.

The cardiac segment is anticipated to account for a share of ~14.11% in 2024. The changing disease profile in the country and increasing cases of chronic non-communicable diseases are anticipated to contribute to the growth of cardiac, anti-diabetic, dermatological, and neurological therapeutic segments.

Market influencers:
Increased affordability, improved accessibility and epidemiological transition are expected to fuel the pharmacy retail market in India during the forecast period. The rise in per capita income and penetration of health insurance coverage has bolstered Indian consumers’ affordability. A significant increase in the number of Indians covered under health insurance has helped propel consumer spending on pharmaceuticals.

With the rise in public healthcare expenditure, pharmaceuticals have become more accessible, thereby fueling the pharmacy retail market, especially in rural areas and tier-II cities. Furthermore, the launch of various patented drugs by international pharmaceutical companies resulted in an incremental increase in pharmaceutical sales.

The growing incidence of chronic diseases like hypertension, diabetes, cardiovascular diseases, and cancer, which requires prolonged medication, is expected to further drive the growth of the pharmacy retail market in India during the forecast period.

The sluggish economic growth in the country, owing to factors like agrarian crisis, retail inflation, and lack of fiscal stimulants, have had a negative impact on the profitability of the pharmacy retail market. Index of industrial production (IIP) growth rate of the pharmaceutical industry has experienced a declining trend; the growth rate declined from 30.4% in FY 2017 to 1.6% in FY 2019.

Furthermore, uncertainty in drug pricing has posed a substantial challenge in the pharmacy retail market by way of affecting investors’ sentiments. The implementation of GST has further burdened pharmacy retailers with a low inventory stock and consequent reductions in profitability.

Emergence of online retailers
The e-pharmacy market in India has evolved from its nascent stage to a promising market with strong growth potential. The influx of investments and a rise in Internet subscribers have helped shape up the e-pharmacy market in the country. Online players like Netmeds, 1mg, PharmEasy and MedLife have recently emerged in the Indian pharmacy retail market.

Along with core online players, various traditional offline companies have expanded their retail operations in the online platform to offer value-added services to customers.

Companies covered
• Apollo Pharmacies Limited
• Emami Frank Ross Limited
• Global Healthline Private Limited
• Medlife
• MedPlus Health Services Private Limited
• Netmeds Marketplace Limited
• Noble Medichem Pvt Ltd. (Noble Plus)
• RWL Healthworld Limited (Fortis Health World)
• Wellness Forever Pharmacy
• 91Streets Media Technologies Private Limited (PharmEasy)

Pharmacy Retail Market in India 2020

The post Pharmacy Retail Market in India 2019 first appeared on CRI Report.

Bio Pharma Market in India 2017

admin — Mon, 20 Aug 2018 07:17:10 +0000

Bio Pharma Market in India 2017 states that while historically the biopharmaceuticals market in the country grew at a CAGR of 15.7%, it is expected to grow at a CAGR of 13.6% between 2016 and 2022. With a large portion of the population falling in the senior citizen category, the need for various healthcare services and pharmaceutical products, including biopharmaceuticals is expected to rise in the country. Moreover, with increased life expectancy, this segment of the population is expected to grow further in the coming years. The increased disposable income of Indians is also allowing them to spend more on medicines and follow medication more diligently. Also, growing health awareness among individuals is resulting in early detection of various medical conditions, and leading to individuals being subject to various medications much earlier than before.
However, the lack of regulatory clarity acts as a major challenge for the industry. The regulation of biopharmaceuticals is inefficient and complex due to the involvement of multiple agencies and committees in the review and approval process. Competition from other Asian countries also acts as a challenge for the Indian bio pharma market. Despite the competition from other countries, India’s biotechnology sector has attracted major investments from several global companies due to its strong generic biotechnology potential. While Indian Immunologicals Ltd. set up vaccine manufacturing facilities in Pondicherry and Hyderabad by investing INR 3 bn and INR 2.5 bn respectively, Shantha Biotechnics Pvt. Ltd. built an insulin product manufacturing facility entailing an investment of INR 4.6 bn. The country is being recognized globally as a preferred outsourcing destination for contract research and manufacturing services. This will further aid in the development of the country’s bio pharma sector. Biocon Ltd., Dr. Reddy’s Laboratories Ltd, Serum Institute of India Pvt. Ltd., Lupin Ltd. and Intas Pharmaceuticals Ltd. are some of the major companies operating in this market.

Coverage:
Overview of the bio pharma market in India, and historical and forecasted market size data over 2010 to 2022
Trade analysis of bio pharma products in India
Qualitative analysis of the major drivers and challenges affecting the market
Analysis of the competitive landscape and profiles of major players operating in the market
Key recent developments in the Indian bio pharma sector

Why Buy?
Get a broad understanding of the bio pharma sector in India, the dynamics of the market and the current state of the sector
Strategize marketing, market-entry, market expansion and other business plans by understanding the factors driving the growth of the market
Be informed regarding the key developments in the Indian bio pharma sector
Understand major competitors’ business and market dynamics, and respond accordinglySlide 1: Executive Summary

Socioeconomic Indicators
Slide 2: Total Population (2010-2011 – 2019-2020), Population Density (2010-2011 – 2019-2020)
Slide 3: Sex Ratio (2005, 2010, 2015, 2020), Population by Age Group (2005, 2010, 2015, 2020), Urbanization Trend (2010-2011 – 2019-2020)
Slide 4: Total Fertility Rate (2005-2010, 2010-2015, 2015-2020), Infant Mortality Rate (2005-2010, 2010-2015, 2015-2020), Total Number of Births (2005-2010, 2010-2015, 2015-2020), Total Number of Death (2005-2010, 2010-2015, 2015-2020)
Slide 5: Total Literacy Rate (2001, 2011), Rural Literacy (2001, 2011), Urban Literacy (2001, 2011)
Slide 6: GDP at Market Prices (2010-2014), FDI (2010-2014), Inflation Rate (2010-2014), Unemployment Rate (2010-2014)
Slide 7: Access to Safe Drinking Water (2001, 2011), Exchange Rate (2010-2015)

Market Overview
Slide 8: Market Definition & Structure
Slide 9: Biopharmaceuticals Market in India – Market Size & Growth (2010 –2022)
Slide 10: Biopharmaceuticals Market in India – Market Overview
Slide 11: Porter’s Five Forces Analysis

Trade Analysis
Slide 12: Export of Vaccines for Human Medicine – Size (Value-Wise; FY 2013 – FY 2017 and Volume-Wise; FY 2013 – FY 2017)
Slide 13: Export of Vaccines for Human Medicine – Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016; and Volume-Wise; FY 2015 and FY 2016)
Slide 14: Import of Vaccines for Human Medicine – Size (Value-Wise; FY 2013 – FY 2017 and Volume-Wise; FY 2013 – FY 2017)
Slide 15: Import of Vaccines for Human Medicine – Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016; and Volume-Wise; FY 2015 and FY 2016)

Market Influencers
Slide 16-17: Market Drivers
Slide 18: Market Challenges

Market Trends
Slide 19: Key Trends

Competitive Landscape
Slide 20: List of Major Players
Slide 21-50: Profiles of Major Players

Recent Developments
Slide 51-52: Recent Developments

Appendix
Slide 53: Research Methodology

The post Bio Pharma Market in India 2017 first appeared on CRI Report.